3 news items
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
CRVS
6 May 24
results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
CRVS
2 May 24
of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CRVS
9 Apr 24
. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including
- Prev
- 1
- Next